Home LiteratureArticle Details
PMID: 18157091 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

CpG island methylation profile of pancreatic intraepithelial neoplasia.

Sato N, Fukushima N, Hruban RH, Goggins M

Abstract

Infiltrating adenocarcinoma of the pancreas is thought to develop through well-defined precursor lesions called pancreatic intraductal neoplasia (PanIN). Despite the exponential growth in our understanding of genetic events that characterize the progression of PanINs to invasive carcinoma, little is known about the role of epigenetic alterations in these precursor lesions. To define the timing and prevalence of methylation abnormalities during early pancreatic carcinogenesis, we investigated the CpG island methylation profile in the various grades of PanINs. Using methylation-specific PCR, we analyzed DNA samples from 65 PanIN lesions for methylation status of eight genes recently identified by microarray approach as aberrantly hypermethylated in invasive pancreatic cancer. Aberrant methylation at any of the eight genes was identified in 68% of all the PanIN lesions examined, and, notably, aberrant methylation was identified in more than 70% of the earliest lesions (PanIN-1A). The average number of methylated loci was 1.1 in PanIN-1A, 0.8 in PanIN-1B, 1.1 in PanIN-2, and 2.9 in PanIN-3 lesions (P=0.01 for PanIN -3 vs earlier PanINs). Among the genes analyzed, NPTX2 demonstrated an increase in methylation prevalence from PanIN-1 to PanIN-2 (P=0.0008), and from PanIN-2 to PanIN-3 for SARP2 (P=0.001), Reprimo (P=0.01), and LHX1 (P=0.03). These results suggest that aberrant CpG island hypermethylation begins in early stages of PanINs, and its prevalence progressively increases during neoplastic progression.

MeSH Terms
Adenocarcinoma/genetics,metabolism Bile Duct Neoplasms/genetics,metabolism Biomarkers, Tumor Chronic Disease CpG Islands/genetics DNA Methylation Disease Progression Gene Expression Regulation, Neoplastic Humans Pancreatic Ducts/metabolism,pathology Pancreatic Neoplasms/genetics,metabolism Pancreatitis/genetics,metabolism Precancerous Conditions/genetics,metabolism Predictive Value of Tests
Chemicals
Biomarkers, Tumor
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Sato Norihiro
Departments of Pathology, Oncology and Medicine, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Fukushima Noriyoshi
Hruban Ralph H
Goggins Michael
References (62)
62 references, click to expand
  1. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase.
    J Biol Chem. 2000 Jul 28;275(30):22627-30 PMID: 10930422
  2. Progressive increases in de novo methylation of CpG islands in bladder cancer.
    Cancer Res. 2000 May 1;60(9):2473-6 PMID: 10811126
  3. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.
    Cancer Res. 2000 Sep 15;60(18):5021-6 PMID: 11016622
  4. Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers.
    Cancer Res. 2001 Mar 1;61(5):1833-8 PMID: 11280733
  5. CpG island methylation in premalignant stages of gastric carcinoma.
    Cancer Res. 2001 Apr 1;61(7):2847-51 PMID: 11306456
  6. Allelic loss is often the first hit in the biallelic inactivation of the p53 and DPC4 genes during pancreatic carcinogenesis.
    Am J Pathol. 2001 May;158(5):1677-83 PMID: 11337365
  7. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions.
    Am J Surg Pathol. 2001 May;25(5):579-86 PMID: 11342768
  8. Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice.
    Gut. 2007 Oct;56(10):1410-4 PMID: 17299058
  9. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer.
    Oncogene. 2001 Jun 7;20(26):3348-53 PMID: 11423985
  10. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium.
    Cancer Res. 2001 Nov 15;61(22):8284-9 PMID: 11719461
  11. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma.
    Cancer Res. 2001 Dec 1;61(23):8540-6 PMID: 11731440
  12. STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas.
    Am J Pathol. 2001 Dec;159(6):2017-22 PMID: 11733352
  13. Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation.
    Am J Pathol. 2002 Jan;160(1):45-50 PMID: 11786397
  14. Concordant CpG island methylation in hyperplastic polyposis.
    Am J Pathol. 2002 Feb;160(2):529-36 PMID: 11839573
  15. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Gastroenterology. 2002 Apr;122(4):1113-21 PMID: 11910361
  16. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology.
    Am J Pathol. 2002 Apr;160(4):1239-49 PMID: 11943709
  17. Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived.
    Oncogene. 2002 Mar 27;21(13):2114-7 PMID: 11960385
  18. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma.
    Am J Pathol. 2002 May;160(5):1573-81 PMID: 12000709
  19. CpG island methylation in aberrant crypt foci of the colorectum.
    Am J Pathol. 2002 May;160(5):1823-30 PMID: 12000733
  20. The fundamental role of epigenetic events in cancer.
    Nat Rev Genet. 2002 Jun;3(6):415-28 PMID: 12042769
  21. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.
    Gastroenterology. 2002 Jul;123(1):365-72 PMID: 12105864
  22. Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia.
    Am J Pathol. 2002 Aug;161(2):399-403 PMID: 12163364
  23. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia.
    Am J Pathol. 2002 Nov;161(5):1541-7 PMID: 12414502
  24. Aberrant methylation of the 5' CpG island of TSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanlNs.
    Cancer Biol Ther. 2002 May-Jun;1(3):293-6 PMID: 12432281
  25. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM.
    J Clin Invest. 2003 Feb;111(4):487-95 PMID: 12588887
  26. Effects of 5-aza-2'-deoxycytidine on matrix metalloproteinase expression and pancreatic cancer cell invasiveness.
    J Natl Cancer Inst. 2003 Feb 19;95(4):327-30 PMID: 12591989
  27. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays.
    Am J Pathol. 2003 Apr;162(4):1151-62 PMID: 12651607
  28. Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice.
    Cancer Biol Ther. 2003 Jan-Feb;2(1):78-83 PMID: 12673124
  29. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues.
    Clin Cancer Res. 2003 Apr;9(4):1446-52 PMID: 12684418
  30. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays.
    Cancer Res. 2003 Jul 1;63(13):3735-42 PMID: 12839967
  31. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms.
    Br J Cancer. 2003 Jul 21;89(2):338-43 PMID: 12865927
  32. Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma.
    Cancer Res. 2003 Jul 15;63(14):4158-66 PMID: 12874021
  33. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
    Oncogene. 2003 Aug 7;22(32):5021-30 PMID: 12902985
  34. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.
    Cancer Res. 2003 Dec 15;63(24):8614-22 PMID: 14695172
  35. Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the pancreas.
    Am J Pathol. 2004 Mar;164(3):903-14 PMID: 14982844
  36. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling.
    Oncogene. 2004 Feb 26;23(8):1531-8 PMID: 14716296
  37. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis.
    Mol Cancer Res. 2004 Apr;2(4):215-24 PMID: 15140943
  38. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach.
    Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 PMID: 15224285
  39. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma.
    Cancer Res. 1997 Jun 1;57(11):2140-3 PMID: 9187111
  40. SARPs: a family of secreted apoptosis-related proteins.
    Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13636-41 PMID: 9391078
  41. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis.
    Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6 PMID: 9751761
  42. Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression.
    Cancer Res. 1998 Oct 15;58(20):4740-4 PMID: 9788631
  43. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma.
    Oncogene. 2005 Jan 27;24(5):850-8 PMID: 15592528
  44. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells.
    Cancer Res. 2005 Mar 1;65(5):1619-26 PMID: 15753353
  45. LigAmp for sensitive detection of single-nucleotide differences.
    Nat Methods. 2004 Nov;1(2):141-7 PMID: 15782177
  46. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.
    Am J Pathol. 2005 Dec;167(6):1739-52 PMID: 16314484
  47. DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease.
    Cancer Res. 2006 Jan 15;66(2):1208-17 PMID: 16424060
  48. Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers.
    Gastroenterology. 2006 Feb;130(2):548-65 PMID: 16472607
  49. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
    Oncogene. 2006 May 18;25(21):3084-92 PMID: 16407829
  50. DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas.
    Carcinogenesis. 2006 Jun;27(6):1160-8 PMID: 16537562
  51. Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas.
    J Hepatobiliary Pancreat Surg. 2006;13(4):280-5 PMID: 16858538
  52. The role of epigenetic alterations in pancreatic cancer.
    J Hepatobiliary Pancreat Surg. 2006;13(4):286-95 PMID: 16858539
  53. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer.
    Am J Surg Pathol. 2006 Sep;30(9):1067-76 PMID: 16931950
  54. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.
    Clin Cancer Res. 2006 Nov 15;12(22):6637-42 PMID: 17121882
  55. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
    J Clin Oncol. 2007 Jan 20;25(3):319-25 PMID: 17235047
  56. Pancreatic adenocarcinoma: update on the surgical pathology of carcinomas of ductal origin and PanINs.
    Mod Pathol. 2007 Feb;20 Suppl 1:S61-70 PMID: 17486053
  57. Molecular genetics of pancreatic intraepithelial neoplasia.
    J Hepatobiliary Pancreat Surg. 2007;14(3):224-32 PMID: 17520196
  58. SPARC, a matricellular glycoprotein with important biological functions.
    J Histochem Cytochem. 1999 Dec;47(12):1495-506 PMID: 10567433
  59. Hypermethylation of multiple genes in pancreatic adenocarcinoma.
    Cancer Res. 2000 Apr 1;60(7):1835-9 PMID: 10766168
  60. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.
    Cancer Res. 2000 Apr 1;60(7):2002-6 PMID: 10766191
  61. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications.
    Am J Pathol. 2000 May;156(5):1767-71 PMID: 10793087
  62. Progression model for pancreatic cancer.
    Clin Cancer Res. 2000 Aug;6(8):2969-72 PMID: 10955772
Article Info
Journal
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
Abbr.
Mod Pathol
ISSN
0893-3952
Published
2008-03-00
Epub
2007-00-21
Pages
238-44
Language
English
Region
United States
NLM ID
8806605
PMCID
PMC2678810
Subset
IM
Grants
NCI NIH HHS · P50 CA062924 · United States
NCI NIH HHS · P50 CA062924-140011 · United States
NCI NIH HHS · P50 CA062924-159002 · United States
NCI NIH HHS · P50 CA062924-150011 · United States
NCI NIH HHS · P50 CA062924-149002 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com